Takeda, Eli Lilly Want Ark. Taxpayer's Actos Suit Nixed

Law360, Los Angeles (June 3, 2013, 9:59 PM EDT) -- Takeda Pharmaceuticals Co. Ltd. and Eli Lilly & Co. urged a Louisiana federal judge on Friday to dismiss a class action alleging they ripped off taxpayers by hiding the risks of their diabetes drug Actos, saying the plaintiff hadn't properly pled violations of an Arkansas constitutional prohibition on misuse of public funds.

Friday’s motion in the multidistrict litigation argues that plaintiff Greg Bowerman failed to properly plead that the pharmaceutical companies had violated the theory of illegal exaction, a cause of action under the state constitution...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Actos (Pioglitazone) Products Liability Litigation


Case Number

6:11-md-02299

Court

Louisiana Western

Nature of Suit

Personal Inj. Prod. Liability

Judge

Rebecca F Doherty

Date Filed

December 29, 2011


Case Title

Bowerman v. Takeda Pharmaceuticals North America Inc et al


Case Number

6:12-cv-01590

Court

Louisiana Western

Nature of Suit

Personal Inj. Prod. Liability

Judge

Rebecca F Doherty

Date Filed

June 15, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.